Novartis Adds Companion Dx to Lumiracoxib Resubmission in Europe
February 04, 2010
Novartis Adds Companion Dx to Lumiracoxib Resubmission in Europe
A Novartis official suggested that the resubmission of lumiracoxib could be the "first example" of a molecular diagnostic-based "drug rescue" in the industry.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Dako, Genentech Partner on Companion Dx FDA Submission for Pertuzumab
December 9, 2011 / GenomeWeb Daily News - Novartis MDx Focuses on Companion Dx as Key Strategic Direction
December 1, 2011 / GenomeWeb Daily News - Novartis Eyeing US Market for Prexige Launch with Companion Test
February 10, 2010 / Pharmacogenomics Reporter - Veridex, Arno Reach Deal to Develop CDx for Anti-Progestins
June 3, 2013 / GenomeWeb Daily News - Qiagen Licenses Two Biomarkers for CDx Development
May 31, 2013 / GenomeWeb Daily News